T. Rowe Price Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $123M | Sell |
2,613,233
-360,597
| -12% | -$17M | 0.01% | 529 |
|
|
2025
Q1 | $116M | Sell |
2,973,830
-369,813
| -11% | -$14.4M | 0.01% | 525 |
|
|
2024
Q4 | $181M | Buy |
3,343,643
+363,394
| +12% | +$19.7M | 0.02% | 451 |
|
|
2024
Q3 | $150M | Buy |
2,980,249
+418,737
| +16% | +$21.1M | 0.02% | 490 |
|
|
2024
Q2 | $113M | Buy |
2,561,512
+425,629
| +20% | +$18.7M | 0.01% | 525 |
|
|
2024
Q1 | $107M | Sell |
2,135,883
-178,129
| -8% | -$8.95M | 0.01% | 534 |
|
|
2023
Q4 | $140M | Buy |
2,314,012
+196,144
| +9% | +$11.8M | 0.02% | 483 |
|
|
2023
Q3 | $121M | Buy |
2,117,868
+174,812
| +9% | +$9.96M | 0.02% | 477 |
|
|
2023
Q2 | $99.1M | Buy |
1,943,056
+1,112,150
| +134% | +$56.7M | 0.01% | 525 |
|
|
2023
Q1 | $17.8M | Buy |
830,906
+8,305
| +1% | +$178K | ﹤0.01% | 945 |
|
|
2022
Q4 | $8.64M | Sell |
822,601
-46,787
| -5% | -$491K | ﹤0.01% | 1079 |
|
|
2022
Q3 | $6.92M | Sell |
869,388
-1,136
| -0.1% | -$9.04K | ﹤0.01% | 1138 |
|
|
2022
Q2 | $4.44M | Buy |
870,524
+304,333
| +54% | +$1.55M | ﹤0.01% | 1434 |
|
|
2022
Q1 | $6.29M | Sell |
566,191
-180,671
| -24% | -$2.01M | ﹤0.01% | 1425 |
|
|
2021
Q4 | $7.39M | Sell |
746,862
-9,441
| -1% | -$93.4K | ﹤0.01% | 1453 |
|
|
2021
Q3 | $7.47M | Hold |
756,303
| – | – | ﹤0.01% | 1462 |
|
|
2021
Q2 | $7.81M | Sell |
756,303
-35,982
| -5% | -$372K | ﹤0.01% | 1445 |
|
|
2021
Q1 | $8.11M | Buy |
792,285
+4,500
| +0.6% | +$46.1K | ﹤0.01% | 1420 |
|
|
2020
Q4 | $8.53M | Buy |
+787,785
| New | +$8.53M | ﹤0.01% | 1364 |
|